Reinach, 5 May 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, has reached a major milestone to boost its commercial performance by signing a multi-year agreement with a leading CMO partner as basis to secure the Vanillin business with a global F&F customer of around CHF 35 million until 2026.
Grace Breeding and Evolva Holdings Partner to Develop Next-Generation, Sustainable Crop Yield and Resilience Solutions
Reinach, 11 October 2022 – Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, has received approval for its NootkaSHIELDTM concept from the Hong Kong regulatory authorities as an active ingredient for use in insecticides and insect repellents. The initial market launch of an application as personal repellent spray is targeted for the first quarter of 2023.
Reinach, November 30, 2021 - Evolva (SIX:EVE), the Swiss biotech companynfocused on the research, development and commercialization of ningredients based on nature, announced today that it has entered into a nPurchase and Subscription Agreement with VERAISON SICAV Engagement Fund n('VERAISON') to purchase 63'751'116 shares in a private placement, nraising gross proceeds in the amount of CHF 7.5m. Evolva also announced nthat Carsten Däweritz, Chief Financial Officer, will depart from the ncompany in May 2022.